InvestorsHub Logo

techisbest

09/19/17 11:24 AM

#650 RE: twointen #647

I forgot about that one because it is only approved for marketing in Asia.

But I would love to see BLFS continue its run with more good news.

The market seems to be noticing. I hope it is more than just a technical run.

Today's news is another "potential" revenue generator. We have a lot of those. It would be great if these customers started getting approvals for their products on a regular basis.

"BOTHELL, Wash., July 13, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced that Kolon Life Science, TissueGene's exclusive licensee for Asia, including Korea, has received marketing approval for Invossa-K Inj., the world's first cell and gene therapy for degenerative arthritis from the Korea Ministry of Food and Drug Safety (MFDS)."